June 2021
Volume 62, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2021
Fluticasone Intravitreal Implant in Patients with Macular Edema Due to Retinal Vein Occlusion
Author Affiliations & Notes
  • Nikisha Kothari
    Retina, Texas Retina Associates, Arlington, Texas, United States
  • Deborah Chong
    Retina, Texas Retina Associates, Arlington, Texas, United States
  • Robert Wang
    Retina, Texas Retina Associates, Arlington, Texas, United States
  • Christopher Fuller
    Retina, Texas Retina Associates, Arlington, Texas, United States
  • Ashkan Abbey
    Retina, Texas Retina Associates, Arlington, Texas, United States
  • Footnotes
    Commercial Relationships   Nikisha Kothari, None; Deborah Chong, None; Robert Wang, None; Christopher Fuller, None; Ashkan Abbey, Alimera (C), Alimera (R)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2021, Vol.62, 3314. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Nikisha Kothari, Deborah Chong, Robert Wang, Christopher Fuller, Ashkan Abbey; Fluticasone Intravitreal Implant in Patients with Macular Edema Due to Retinal Vein Occlusion. Invest. Ophthalmol. Vis. Sci. 2021;62(8):3314.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate the outcomes of use of the fluticasone acetate implant in eyes with macular edema from retinal vein occlusion.

Methods : We retrospectively reviewed 13 eyes with macular edema from retinal vein occlusion who received an injection with the fluticasone implant. We evaluated visual acuity and central retinal thickness outcomes and documented complications including cataract progression and increased intraocular pressure (IOP).

Results : Visual acuity improved following injection with the fluticasone implant at final follow up (0.39 vs 0.26, p= 0.02). In addition, central retinal thickness improved by 6 months, but then increased by final follow up (412mm, 302mm p=0.01, 345mm p=0.3). In all phakic patients, cataract progression was seen and required phacoemulsification surgery. Seven (53%) patients required IOP lowering medications and two (15%) required glaucoma filtration surgery.

Conclusions : Our study found the use of the fluticasone implant to be safe and effective for the management of macular edema from retinal vein occlusion. Further larger, randomized controlled studies are required to further evaluate their efficacy.

This is a 2021 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×